Viracta Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

 

SAN DIEGO, Sept. 9, 2020 /PRNewswire/ -- Viracta Therapeutics Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, today announced that Ivor Royston, MD, President and Chief Executive Officer of Viracta, will present a corporate overview at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, 2020 at 3:00 pm ET.  

About Viracta Therapeutics, Inc.

Viracta is a precision oncology company targeting virus-associated malignancies. The Company's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphomas. Viracta is pursuing application of this kick and kill approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma and gastric carcinoma, and other viral-related cancers.

For additional information please visit www.viracta.com.

Media and Investor Contact:

 Amy Conrad
Juniper Point
amy@juniper-point.com 
858-366-3243

Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com 
(212) 915-2569

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/viracta-therapeutics-to-present-at-the-hc-wainwright-22nd-annual-global-investment-conference-301125916.html

SOURCE Viracta

 

Back to news